• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Galera Therapeutics Inc.

    4/16/24 4:39:49 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRTX alert in real time by email
    SC 13G 1 alpi_sc13g.htm SCHEDULE 13G Schedule 13G

     

    OMB APPROVAL

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549 

    OMB Number:3235-0145 

    Expires:Febuary 28, 2009 

    Estimated average burden
    hours per response ....10.4

     

     

    SCHEDULE 13G

    Under the Securities and Exchange Act of 1934

    (Amendment No.                 )*

     

    GALERA THERAPEUTICS INC.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    36338

    (CUSIP Number)

     

     

    March 22, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o  Rule 13d-1(b)

    o  Rule 13d-1(c)

    o  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1


     

    CUSIP No.   36338

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    ALPHA PHARMA INVESTMENTS LLC  -  EIN: 99-1963468 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationU.S.A. 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power2,750,000 

    6.Shared Voting Power 

    7.Sole Dispositive Power2,750,000 

    8.Shared Dispositive Power 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9) 

    5.056% 

    12.Type of Reporting Person (See Instructions) 

    PN 


    2


     

    Item 1.

    The name and address of the principal executive offices of the Issuer are:

    GALERA THERAPEUTICS INC.

    45 LIBERTY BLVD, SUITE 230

    MALVERN, PA 19355

    Item 2.

    This statement on Schedule 13G is being filed by:

     

    (a)Name: 

    R SOFER

    (collectively, the “Filers”)

     

     

    (b)Address: 

    9559 COLLINS AVE 1009S

    MIAMI, FL 33154

     

    (c)Citizenship/Place: 

    U.S.A.

     

    (d)Title of Class of Securities: 

    Common Shares, $0.001 par value per share

     

    (e)CUSIP Number: 

    36338D108

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)oBroker or dealer registered under section 15 of the Act (15 U.S.C. 78o). 

    (b)oBank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). 

    (c)oInsurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 

    (d)oInvestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 

    (e)oAn investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 

    (f)oAn employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 

    (g)oA parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

    (h)oA savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)oA church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

    (j)oGroup, in accordance with §240.13d-1(b)(1)(ii)(J). 

    Item 4.  Ownership

    See Items 5-9 and 11 of the cover page for each Filer.

    The sum totals for all filers are as below.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)Amount beneficially owned:    2,750,000 

    (b)Percent of class:   5.056% 

    (c)Number of shares as to which the person has: 


    3


    (i)Sole power to vote or to direct the vote:   2,750,000 

    (ii)Shared power to vote or to direct the vote:   0 

    (iii)Sole power to dispose or to direct the disposition of:   2,750,000 

    (iv)Shared power to dispose or to direct the disposition of:   0 


    4


    Item 5.  Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  o

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8.  Identification and Classification of Members of the Group

    Not applicable.

    Item 9.  Notice of Dissolution of Group

    Not applicable.

    Item 10.  Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    5


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:April 15, 2024 

    By:/s/ R Sofer     

    C/O ALPHA PHARMA INVESTMENTS 

     


    6

    Get the next $GRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRTX

    DatePrice TargetRatingAnalyst
    8/10/2023$6.00 → $0.50Overweight → Neutral
    Piper Sandler
    12/20/2021$11.00 → $20.00Buy
    Citigroup
    12/15/2021$10.00Neutral → Buy
    HC Wainwright & Co.
    12/15/2021$15.00Neutral → Buy
    BTIG
    10/20/2021Buy → Neutral
    HC Wainwright & Co.
    10/19/2021$17.00 → $2.00Buy → Underperform
    BofA Securities
    10/19/2021Buy → Neutral
    BTIG Research
    More analyst ratings

    $GRTX
    Financials

    Live finance-specific insights

    See more
    • Galera Therapeutics completes acquisition of Nova Pharmaceuticals

      Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical's Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer. Concurrent financing when added to Galera's existing cash balance, is anticipated to fund operations through data readout of its lead program and into 2026. Galera intends to leverage NCI grants, academic partnerships and the I-SPY 2 network for efficient and cost-effective clinical dataset expansion. MALVERN, Pa.

      12/31/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Adopts Limited Duration Stockholder Rights Agreement

      MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the "Board") has unanimously resolved to adopt a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock and the Rights Agreement is intended to enable all Galera stockholders to realize the full potential value of their investment in the comp

      5/3/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

      The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its cash runway and continue enrolling its rucosopasem clinical trials Conference call tomorrow, August 10, 2023 at 8:30 a.m. ET MALVERN, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food an

      8/9/23 4:31:52 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chang Nancy T bought $499,979 worth of shares (7,644,932 units at $0.07) (SEC Form 4)

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      1/2/25 4:12:36 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schneid Yair bought $590,424 worth of shares (2,780,407 units at $0.21), increasing direct ownership by 35% to 10,823,610 units (SEC Form 4) (Amendment)

      4/A - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/1/24 5:02:03 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schneid Yair bought $166,417 worth of shares (932,402 units at $0.18), increasing direct ownership by 13% to 8,043,203 units (SEC Form 4)

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      2/26/24 4:06:04 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Leadership Updates

    Live Leadership Updates

    See more

    $GRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Galera Expands Commercial Leadership Team

      Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products New Drug Application (NDA) for avasopasem is currently under priority review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee (PDUFA) target date of August 9, 2023 MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of accomplished pharmace

      5/1/23 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer

      MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer (CMO). Dr. Kennedy is a renowned Johns Hopkins-trained surgical oncologist and former Chief of Pancreatic and Hepatobiliary Surgery at Thomas Jefferson University with over 15 years' experience in clinical development and biopharma leadership. He will succeed Jon T. Holmlund, M.D., who will retire at the end of this yea

      9/1/22 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer

      MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer (CCO) and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer (CLCO) and Secretary. Both executives join Galera with over 25 years of leadership experience within the biopharmaceutical industry. "We are thrilled to welcome Mark and Jennifer to Galera at this critical point in the Company's growth," sa

      10/12/21 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Sussman Joel F.

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/5/25 4:19:43 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Sorensen Mel

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/5/25 4:17:46 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lokay Kevin G

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      2/26/25 4:57:11 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Therapeutics completes acquisition of Nova Pharmaceuticals

      Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical's Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer. Concurrent financing when added to Galera's existing cash balance, is anticipated to fund operations through data readout of its lead program and into 2026. Galera intends to leverage NCI grants, academic partnerships and the I-SPY 2 network for efficient and cost-effective clinical dataset expansion. MALVERN, Pa.

      12/31/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Announces Board Approval of Complete Liquidation and Dissolution

      MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company under Delaware law, and plans to seek stockholder approval of the Plan of Dissolution at a special meeting of stockholders to be held on or around October 17, 2024. If the Plan of Dissolution is approved by the Company's stockholders, the Company intends t

      8/14/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

      MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. "Our review of strategic options continues, as we strive to maximize value for our stockholders," said Mel Sorensen, M.D., Galera's President and CEO. "Potential options may include mergers, asset sales, divestiture, licensing arrangements, or other strategic transactions and may encompass a potential development path

      5/13/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

      SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/16/24 10:26:17 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Galera Therapeutics Inc.

      SC 13G - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/16/24 10:25:53 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

      SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/1/24 5:01:34 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    SEC Filings

    See more
    • SEC Form 8-K filed by Galera Therapeutics Inc.

      8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

      4/2/25 5:05:17 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Galera Therapeutics Inc.

      10-K - Galera Therapeutics, Inc. (0001563577) (Filer)

      3/31/25 4:30:34 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Galera Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K/A - Galera Therapeutics, Inc. (0001563577) (Filer)

      3/24/25 6:13:44 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Galera downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Galera from Overweight to Neutral and set a new price target of $0.50 from $6.00 previously

      8/10/23 7:27:44 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Galera Therapeutics with a new price target

      Citigroup reiterated coverage of Galera Therapeutics with a rating of Buy and set a new price target of $20.00 from $11.00 previously

      12/20/21 9:46:24 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Therapeutics upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Galera Therapeutics from Neutral to Buy and set a new price target of $10.00

      12/15/21 6:42:14 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care